Title: IMAGING BRAIN TUMORS IN NEWBORNS AND EARLY CHILDHOOD: UTILITY OF COMBINING MR TECHNIQUES
1IMAGING BRAIN TUMORS IN NEWBORNS AND EARLY
CHILDHOOD UTILITY OF COMBINING MR TECHNIQUES
- M. MORTILLA, M. ANTONELLO, C. CESARINI,
- L. TASCIOTTI, C. FONDA
- UNIVERSITY CHILDRENS HOSPITAL A. MEYER
- FIRENZE, ITALY
2INTRODUCTION
In the childhood CNS tumors are the leading
cause of cancer-related death. In the last 20
years the advances in neuroimaging, neurosurgery,
radiation therapy and chemotherapy have
considerably improved the long term survival of
children with brain tumors. Conventional MR
images show definite details of brain tumor
location, extension and morphological
characteristics. Therefore MR imaging is widely
used in the diagnosis and follow-up of pediatric
patients with brain tumors.
3Since conventional MRI does not provide
information about tissue chemistry and the
interpretation of these images may lead to poor
estimation of the extent of active tumor, non
conventional techniques, such as diffusion images
and proton spectroscopy, may be used contributing
to more accurate diagnosis, prognostication and
treatment planning. Tissue diagnosis remains the
gold standard. The purpose of the study is to
find a role of Diffusion-weighted Imaging (DWI)
and proton Spectroscopy in characterizing
intracerebral masses and finding a correlation
between these techniques and histologic analysis
of tumors.
4PATIENTS METHODS
62 patients affected with brain tumors aged 1
month-6 years, were studied with a 1.5T MR
scanner (Eclipse, Philips) operating at 27mT/m
gradient strenght and 40 mT/m/ms slew rate. A
quadrature head coil was used. T2w SE images,
FLAIR, T1w SE pre and post Gadolinium injection
and sometimes GE T2 were obtained. Proton
Spectroscopy studies included single voxel
studies (PRESS TE 40/135/270ms, STEAM TE 20ms)
and/or CSI (PRESS TE 135/270.
5Spectroscopy acquisition were performed before
the injection of the contrast media. Eight
children were able to undergo to the MR without
need of sedation despite the long duration of the
exam (50-60 minutes). The other children were
sedated with different modalities regarding
weight, age and critical conditions patients up
to 18 months of age (if the weight was below
10Kg) were sedated with chlorale hydrate (50-100
mg/Kg), while from 18mo. to 6yrs. patients were
sedated using Sevoflurane through laringeal mask
or, rarely, with barbiturates i.v.
6Echo planar Imaging of Diffusion were obtained
with sensitization along the slice select, read
out and phase encoding axes (b- value of
800/1000/1200) with Echo Planar Single Shot
sequences (TR 6450ms, TE 145.8ms, FA 90, 5mm/1mm
slice thickness/gap, 81x81 gt 128x 128
reconstruction matrix, 1 NEX, chemical saturation
at FA 180, FAT saturation) with a total
acquisition time of 32 seconds/15 slices.
7In all patients a set of 3 images along the long
orthogonal axes of gradient sensitization were
obtained and the DWI TRACE images were
post-processed. Apparent Diffusion Coefficient
(ADC) images along the same orthogonal axes were
also obtained and synthetic ADC map was produced
(ADC TRACE. ADC values are expressed as a number
x 10-3mm2/sec.
8Multivoxel (CSI) were acquired with PRESS
sequence, TR 1500ms, TE 135ms, FA 90, thickness
1-1.5 cm, FOV 15 to 20cm. Chemical shift imaging
matrix size 16x16, signal averages 1/2 with 1
slice per batch. Single voxel were acquired with
PRESS sequence, TR 1500/2000ms, TE 270/135/40ms
and with STEAM TE 20ms, FA 90 acquisition
volume from 20x20x20mm, signal averages 128 and
reference averages 8.
9Most of the tumors underwent to surgery
excision and the specimens were analyzed by an
expertise in pathology in order to make diagnosis
following the WHO classification and to determine
cell counting expressed as mean value (m.v.) over
an are of 0.083mm2. Some tumors were biopsied
only, such as germinoma because they are highly
responsive to therapy. Biopsy or surgical
excision was not performed when the tumor arised
from non resectable regions (hypotalamus,
brainstem,..)
10OUR CASES
-
- Craniopharingioma 5
- Low grade glioma (WHO I) 11
- Glioma WHO II 2
- High grade glioma 1
- Pylocitic astrocytoma 10
- Medulloblastoma (MB-PNET) 11
- Germinoma 1
- Subependimal gigantic astrocytoma 2
- Ganglioblastoma 1
- Ganglioglioma 1
- Dysplasia 3
- DNET 2
- Teratoma 1
- Metastasi 1
- Altri 10
11Diffusion-weighted Imaging
It has been reported that the ADC characterizes
the biophysical characteristics of tissue
microstructure and microdynamics and that it
provides information (based on pathophysiologic
characteristics) that differs from that obtained
with contrast-enhancing imaging. It has been
suggested that the minimum ADC value of
high-grade gliomas is significantly higher than
that of low-grade gliomas and that low ADC values
were found in areas of increased cellularity.
12Others have suggested that the ADC may assist in
the early detection of responses to anticancer
therapy, because an increase in ADC values has
been noted after treatment. DWI measures the
molecular mobility of extracellular
water,alterations in water mobility appear to
reflect treatment-induced changes in tissue
structure. Current understanding is that water
diffusion increases acutely in tumor responsive
to therapy. This precede changes in tumor volume.
131H-MRS (proton magnetic resonance spectroscopy)
- 1H-MRS (Magnetic Resonance Spectroscopy)
provides a qualitative and quantitative
evaluation of brain chemistry - In a proton spectrum at 1.5T the metabolites are
spread out between 63 and 64 MHz, and near 300
MHz at 7T - The resonant frequencies are expressed in part
per million (ppm), and are read from right to
left
141H-MRS
- Fat and water are eliminated, because their
peaks are to high and in spectrum scaling the
brain metabolites would be invisible - The water suppression is obtained with CHESS
(Chemical Shift Selective) or IR (Inversion
Recovery) techniques - The peaks are separated into the individual
frequencies through a Fourier Transform - The magnetic field felt by the Protons in
different molecules depends on electron clouds
related to their different molecular position -gt
different chemical shift -gt spread of single
peaks over the ppm or hertz scale
15Sequences in 1H-MRS
- STEAM (Stimulated Echo Acquisition Mode) 90o
refocusing pulse, short echo time, less
signal-to-noise ratio - PRESS (Point Resolved Spectroscopy) 180o
refocusing pulse, short and long echo time - With short echo time (TE 20-40 ms) metabolites of
both short and long T2 are visualized - With long echo time (TE 270 ms) only metabolites
with long T2 are seen . Echo Time of 135 ms
allows the separation of lactate doublet from
lipids peaks with phase inversion. - TE 65 ms increases sensitivity in lipid detection
nulling lactate
16voxel
- MR Spectra may be acquired with a single voxel
localized in region of interest (normal or
pathological) with variable volume (usually of
2x2x2 cm or more). Small volume are characterized
by less signal to noise ratio. Large volumes
experience higher averaging and are not indicated
for higher resolution data collection, but only
for mean value in a defined area
17multivoxel
- MR Spectra may be acquired within a brain slice
in 2D acquisition or more slices in 3D
acquisition) with variable matrix and variable
volume (usually of 1x1x1 cm or more) Small volume
of voxels experience lower averaging than single
voxel with larger volume. Chemical Shift Imaging
(CSI) may create the metabolite maps with direct
visualization of peak concentration - Magnetic field inhomogeneity, insufficient
shimming and lipids contamination frequently
alter the quality of multivoxel spectra.
18- Many metabolites may be identified in the proton
magnetic resonance at 1.5 tesla, NAA, Cho, Cr,
Lactate, myo-Inositol, Lipids are currently
evaluated - In the following slides there is a list brain
peaks
19List of metabolites that can be individualized
by 1H-MRS
- N-acetyl methylgroups
- (NAA N-acetylaspartate and NAAG
N-acetylaspartylglutamate) - Methyl and Methylene protons of total creatine
(Cr PCr) - Trimethylammonium groups Choline containing
(Cho) - Myo-Inositol (mI)
- Glycine co-resonating with main mI peak (Gly)
- Glutamate Glutamine with a and b-/g- protons
(Glu/Gln) - Glucose
- Scyllo-inositol
- Lactate
- GABA
- Glutathione
- Taurine
- Homo-carnosine
- Phospho-ethanolamine
- Macromolecules
- Lipids
20Resonance intensitiesexpressed in ppm at 1.5T
- Lactate/lipids 1.33
- NAA 2.02
- Glx 2.2-2.4
- Cr/PCr 3.02
- Cho 3.22
- mI 3.56
21Control 5 yrs old CSI PRESS TE 135ms
22- NAA(N-acetyl aspartate) free aminoacid, high CNS
concentration (just less to glutamate) - in adults in neural tissue, axons and dendrites
- in brain maturation also in oligodendrocytes type
2 and in non neuronal cells (mast cells) - used as neuronal marker
23- Cho (choline - N(CH3)3 GPC,PC) cellular membrane
turnover marker - High in tumors, demyelinating processes,
inflammation - Cr ( creatine - Cr PCr k), reference internal
due to its stability, marker of byproducts of
energy chains gtATP - Lac (Lactate) expresses the anaerobic metabolism
24- mI (myo inositol) glial pool marker. Small
amounts from glycine - Glu or Glx (glutamate) neurotransmitter,
intermediate in aminoacid catabolism - Gln (glutamine) metabolism of glutamate glial
marker
25 PRESS TE 135ms
STEAM TE 20ms
? Cho ? Lac ? NAA
4 years old girl pilocytic astrocytoma Lactate
in solid nodule High choline peak In P.A. the
Choline Levels are usually below 3.0, while in
MB-PNET are usually higher
b
a
c
26Mean ADC value 1.68 10-3 mm2 /sec
DWI TRACE
ADC TRACE
215 m.v.
4y.o. girl pilocytic astrocytoma. Histologic
surgical specimen and cell density counting
over mixoid (185 cells) and more compact (215
cells) portion of the tumor.
185 m.v.
Nr. of cell 0.083mm2
27PRESS TE 270ms
PRESS TE 135ms
Boy, 13 months BRAINSTEM GLIOMA Cho/Cr NAA/Cr Lac
MRS data indicates that it
could be a pilocytic astrocytoma
28 6 years old boy Brainstem glioma
1st MRI diagnosis (WHO I) 2ndafter chemo High
Cho 3rd6mo. after Stop Therapy Higher Cho,
low NAA, high lac
FLAIR C.E. FSE T1 ADC TRACE
PRESS TE 270ms
29DWI TRACE ADC TRACE
DWI TRACE ADC TRACE
At diagnosis b 800 DWI ADC
After chemotherapy
306 years old girl glioma of the midbrain (WHO I)
Mild reduction of NAA/Cr and mI/Cr
PRESS TE 40ms
31Boy, 4 years old Astrocytoma WHO II-III
Important reduction of NAA/Cr and moderate
increase of Cho/Cr
32b
VOXEL 8
STEAM TE 20 ms
CSI PRESS TE 270 ms
6 years old boy medulloblastoma
CSI PRESS TE 270ms high choline peak (Cho/Cr
4.09), low NAA intensity signal. Small amount of
lactate. STEAM TE 20ms evident lipids peak.
a
33a
DWI TRACE
ADC TRACE
Mean ADC value 1.2 10-3 mm2 /sec
Medulloblastoma.
750 m.v.
Nr. of cell 0.083mm2
34 PRESS TE 135ms
b
STEAM TE 20ms
6 years old girl. PNET-MB
..
STEAM 20 evident mI, lipids and Glx peaks PRESS
TE 135ms high choline peak (Cho/Cr 12.4) and low
NAA intensity signal.
a
35STEAM TE 20ms
PRESS TE 135ms
11 months old girl pinealoblastoma.
PRESS 135 high choline peak (Cho/Cr 2.6), low
NAA signal intensity. Presence of lactate.
STEAM 20 evident lipids and mI peaks.
36Mean ADC value 0.4 x 10-3 mm2 /sec
DWI TRACE
ADC TRACE
Pinealoblastoma
900 m.v.
Nr. of cell 0.083mm2
376 years old girl choroid plexus carcinoma.
All metabolites, included Creatine, but Choline
are reduced Cho/Cr 31.5
Mean ADC value 1.0 10-3 mm2 /sec
PRESS TE 135ms
reduced Cr
neoplasm do not produce NAA
385 years old girl germinoma.
PRESS TE 135ms
high lipids signal.
Mean ADC value 0.57 10-3 mm2 /sec
Nr. of cell 0.083mm2
320 m.v.
39Cho/Cr 6.1 Lac/Cr 6.8 NAA/Cr
CSI PRESS TE 135ms
PRESS TE 270ms
Girl, 23 months metastasis from rabdomyosarcoma
40Cortical Dysplasia TAYLOR TYPE
Increased mI/Cr ratio
STEAM TE 20ms
41STEAM TE 20ms
PRESS TE 40ms
Boy, 20 months Tuberous sclerosis Increased
mI/Cr ratio
42 ADC vs.Cells number correlation
Germinoma
more highly cellular gt smaller intercellular
spaces gt lower ADC
JDGG
Pinealoblastoma
PNET
MB-PNET
Pylocitic Astrocytoma (solid portion)
43BRAIN ABSCESS vs. TUMOR
a
b
DWI ADC
DWI is able to discriminate between abscesses and
tumors a) brain abscess b) supratentorial
ependymoma
44Boy, 6 years old brain abscess
Most of the metabolites are reduced. Lipids and
lactate are present
45Conclusions
Brain tumors in children are highly heterogeneous
for histology, prognosis and therapeutic
response. Diagnosis and therapy of those, most of
which are low grade, can be complicated because
of their frequent adjacent location to crucial
structures that limits biopsy. The utility of
combining data from biologically important
intracellular molecules, obtained with proton MR
spectroscopy and from water mobility, obtained
with diffusion imaging, is clearly addressed to
increase the diagnostic accuracy in determining
the clinical grade of pediatric brain tumors.
46DWI enable to better differenciate between low-
grade and high-grade tumor high-grade gliomas
have lower ADC values than low-grade gliomas. ADC
maps are easily generated from routine fast
diffusion-weighted imaging by use of software
available on many MR systems. ADC may be a more
direct indicator of changes in the brain than are
other physical parameters. The degree of
diffusion is strongly affected by microscopic
biological structures such as the number, type
and spatial arrangement of cells. These
structures create barriers to the free diffusion
of water so changes in diffusion may more
directly reflect changes occurring within and
between cells.
47It still debating if ADC measurement can be used
to determine the extent of tumor infiltration and
to differentiate infiltration from peritumoral
edema. It has been suggested that tumor
infiltration is characterized by lower ADC values
than edema. In our experience we found that quite
often this is true but we always prefer to be
cautious adding spectroscopy data when is
possible to perform CSI. We also utilize
high-b-value DWI that increase the anisotropy so
is more accurate in the assessment of
infiltration. Since infiltration occurs within
and along white matter tracts, diffusion tensor
imaging may yield more useful information.
48Proton MR Spectroscopy enables the measurements
of multiple chemical metabolites in normal and
abnormal brain parenchyma. Cho/Cr or Cho/NAA in a
lesion correlate with higher cellular
proliferation rate and reflect the presence of a
more malignant and rapidly growing tumor. It is
necessary to correlate MRI data since pilocytic
astrocytoma has high Choline and lactate despite
it is considered benign usually Cho/Cr ratio is
less than 3. NAA is considered a neuronal marker,
which decreases with replacement of neurons by
tumor (or other non-neuronal tissue, including
necrosis). In choroid plexus carcinoma a very low
NAA/Cr is characteristic since the tumor does not
produce NAA.
49MRS can be used to follow tumors over time, since
patients can serve as their own control after
obtaining a baseline scan. CSI may be useful in
monitoring the surgical scar elevation of Cho/Cr
ratio is index of a relapse. We have found this
index reliable mostly in anaplastic ependymoma.
It has been suggested that children with higher
total creatine levels are more responsive to
radiation or chemotherapy. In our experience
children with low-grade gliomas that have
significantly higher baseline Cho/Cr ratio have
more chance to have tumor that progress over 2
years than those that have stable tumors. Lactate
is no more considered an indicator of malignancy
since it is found in benign tumors such as
pilocytic astrocytoma.
50Lipids may be detected in enhancing and non
enhancing tumor regions. For a reliable detection
of lipid peak it would be better to use
acquisition protocols with a TE 65ms that null
lactate peak. Lipids represent microscopic tumor
cell necrosis or membrane breakdown that may
precede necrosis. Lipids may be present in viable
tumor, presumably because of poor perfusion and
hypoxia and they undergo major intensity changes
during apoptosis. They are found also in
radiation necrosis. Because glial tumors are
grade according to their cellularity,
proliferative activity and degree of necrosis,
Cho mapping (increased cellularity and
proliferative activity) may added value to MRI in
childrens with brain tumors, especially when it
is combined with lipid mapping (necrosis and/or
apoptosis).
51Selected References
- Arnold DL, De Stefano N. Magnetic resonance
spectroscopy in vivo applications in
neurological disorders. Ital J Neurol Sci 1997
18 321-329 - Ashwal S, Holshouser B, Tong K, Serna T,
Osterdock R, Gross M, Kido D. Proton spectroscopy
detected myoinositol in children with traumatic
brain injury. Pediatric Research 2004 56630-638 - Astrakas LG, Zurakowski D, Tzika AA, Zarifi MK,
Anthony DC, De Girolami U, Tarbell NJ, Black PM.
Noninvasive magnetic resonance spectroscopic
imaging biomarkers to predict the clinical grade
of pediatric brain tumors. Clin Cancer Res. 2004
Dec 1510(24)8220-8. - Barkovich AJ, Good WV, Koch TK, et al.
Mitochondrial disorders analysis of their
linical and imaging characteristics. AJNR 1993
14 1119-1137 - Bottomley PA. Spatial localization in NMR
spectroscopy in vivo. Ann NY Acad Sci 1987 508
333348 - Bottomley PA. Spatial localization in NMR
spectroscopy in vivo. Ann NY Acad Sci 1987 508
333-348 - Brooks WM, Friedman SD, Gasparovic C. Magnetic
resonance spectroscopy in traumatic brain injury.
J Head Trauma Rehabil 2001 16146164 - Castillo M, Kwock L, Scatliff J, Mukherji SK.
Proton MR spectroscopy in neoplastic and
non-neoplastic brain disorders. Magn Reson
Imaging Clin N Am. 1998 6(1)1-20 - Cecil KM, Jones BV. Magnetic resonance
spectroscopy of the pediatric brain. Top Magn
Reson Imaging 200112435452 - Cendes F, Andermann F, Preul MC, et al.
Lateralization of temporal lobe epilepsy based on
regional metabolic abnormalities in proton
magnetic resonance spectroscopic imaging. Ann
Neurol 1994 35 211-216 - Frahm J, Hanefeld F. Localized proton magnetic
resonance spectroscopy of cerebral metabolites.
Neuropediatrics 1996 27 64-69 - Grodd W, Krageloh-Mann I, Klose U, et al.
Metabolic and destructive brain disorders n
children findings with localized proton MR
spectroscopy. Radiology 1991 81 173-181 - Howe FA, Maxwell RJ, Saunders DE, et al. Proton
spectroscopy in vivo. Magn Reson Q 1993 9
31-59 - Hunter JV, Wang ZJ. MR spectroscopy in pediatric
neuroradiology. Magn Reson Imaging Clin N Am.
2001 9(1)165-89 - Hwang JH, Egnaczyk GF, Ballard E, Dunn RS,
Holland SK, Ball WS Jr. Proton MR spectroscopic
characteristics of pediatric pilocytic
astrocytomas. AJNR Am J Neuroradiol. 1998
19(3)535-40 - Kadota T, Horinouchi T, Kuroda C. Development and
aging of the cerebrum assessment with proton MR
spectroscopy. AJNR Am J Neuroradiol
200122128135 - Kreis R, Ernst T, Ross BD. Development of the
human brain in vivo quantification of metabolite
and water content with proton magnetic resonance
spectroscopy. Magn Reson Med 1993 30 424437 - Kruse B, Hanefeld F, Christen HJ, et al.
Alterations of brain metabolites in
metachromatic leukodystrophy as detected by
localized proton magnetic resonance spectroscopy
in vivo. J Neurol 1993 241 68-74
52- Leonard JC, Younkin DP, Chance B, Subramanian VH,
Leigh JS Jr, Alavi A, Kressel HY, Zimmerman R,
Delivoria-Papadopoulos M. Nuclear magnetic
resonance an overview of its spectroscopic and
imaging applications in pediatric patients. J
Pediatr. 1985 106(5)756-61. - Moore GJ. Proton magnetic resonance spectroscopy
in pediatric neuroradiology. Pediatr Radiol. 1998
Nov28(11)805-14. - Norfray JF, Tomita T, Byrd SE, Ross BD, Berger
PA, Miller RS. Clinical impact of MR spectroscopy
when MR imaging is indeterminate for pediatric
brain tumors. AJR Am J Roentgenol 1999 173 119
125 - Norfray JF, Tomita T, Byrd SE, Ross BD, Berger
PA, Miller RS. Clinical impact of MR spectroscopy
when MR imaging is indeterminate for pediatric
brain tumors. AJR Am J Roentgenol. 1999
173(1)119-25 - Novotny E, Ashwal S, Shevell M. Proton magnetic
resonance spectroscopy an emerging technology in
pediatric neurology research. Pediatr Res. 1998
44(1)1-10 - Penrice J, Cady EB, Lorek A, Wyelinska M, Amess
P, Aldridge R, Stewart A, Wyatt J. Proton
magnetic resonance spectroscopy of the brain in
normal preterm and term infants and early changes
after perinatal hypoxia-ischemia. Pediatr Res
1996 40 614 - Pietz J, Kreis R, Schmidt H, Meyding-Lamadé UK,
Rupp A, Boesch C. Phenylketonuria findings at MR
imaging and localized in vivo H-1 MR spectroscopy
of the brain in patients with early treatment.
Radiology 1996 413420 - Pouwels PJ, Frahm J. Regional metabolite
concentrations in human brain as determined by
quantitative localized proton MRS. Magn Reson Med
1998395360 - Rand SD, Prost R, Li SJ. Proton MR spectroscopy
of the brain. Neuroimaging Clin N Am. 1999
9(2)379-9 - Robertson NJ, Lewis RH, Cowan FM, Allsop JM,
Counsell SJ, Edwards AD, Cox IJ. Early increases
in brain myo-inositol measured by proton magnetic
resonance spectroscopy in term infants with
neonatal encephalopathy. Pediatr Res. 2001
50(6)692-700. - Ross BD. Biochemical considerations in 1H
spectroscopy. Glutamate and glutamine
myo-inositol and related metabolites. NMR Biomed
1991 4 5963 - Ross BD. Biochemical considerations in 1H
spectroscopy. Glutamate and glutamine
myo-inositol and related metabolites. NMR 1991
Biomed 4 59-63 - Rutherford MA, Pennock JM, Counsell SJ, Mercuri
E, Cowan FM, Dubowitz LMS, Edwards AD. Abnormal
magnetic resonance signal in the internal capsule
predicts poor neurodevelopmental outcome in
infants with hypoxic-ischemic encephalopathy.
Pediatrics 1998 102 323328 - Saunders DE, Howe FA, van den Boogaart A,
Griffiths JR, Brown MM. Discrimination of
metabolite from lipid and macromolecule
resonances in cerebral infarction in humans using
short echo proton spectroscopy. J Magn Reson
Imaging 1997 7 11161121 - Thompson JE, Castillo M, Kwock L. MR spectroscopy
in the evaluation of epilepsy. Magn Reson Imaging
Clin N Am. 1998 6(1)21-9. - Tzika A, Astrakas L, Kieran M, Zurakowski D,
Zarifi M, Poussaint T Choline to
n-acetylaspartate ratio is predictive of
pediatric brain tumor progression. Radiology
2001 221(Suppl)488 - Tzika AA, Ball WS Jr, Vigneron DB, et
al.Childhood adrenoleukodystrophy assessment
with proton MR spectroscopy. Radiology 1993 189
467-480 - Tzika AA, Zarifi MK, Goumnerova L, Astrakas LG,
Zurakowski D, Young-Poussaint T, Anthony DC,
Scott RM, Black PM. Neuroimaging in pediatric
brain tumors Gd-DTPA-enhanced, hemodynamic, and
diffusion MR imaging compared with MR
spectroscopic imaging. AJNR Am J Neuroradiol.
200223(2)322-33 - Warren KE. NMR spectroscopy and pediatric brain
tumors. Oncologist 2004 9(3)312-8.